RESUMEN
Next-day residual effects of single evening doses of 3 mg of eszopiclone, 7.5 mg of zopiclone, and placebo were assessed in a randomized, double-blind, placebo-controlled, 3-way crossover study that used a mild sleep restriction protocol (sleep duration, 7 hours). During each period, 91 healthy volunteers spent 2 consecutive nights in the laboratory with time in bed restricted to 7 hours. Volunteers completed the Continuous Tracking Test, Critical Flicker Fusion task, Digit Symbol Substitution Test, N-back tasks, and Linear Analogue Rating Scales every half-hour from 7.5 to 11.5 hours after dose, commencing 15 minutes after awakening. Nighttime dosing of both eszopiclone (3 mg) and racemic zopiclone (7.5 mg) was associated with next-day performance impairment, and these residual effects dissipated over time. Eszopiclone did not differ from zopiclone on the primary end point, mean Continuous Tracking Test tracking error averaged from 7.5 to 9.5 hours after dose; however, a prespecified post hoc parametric analysis of reciprocal-transformed data favored eszopiclone over racemic zopiclone (P = 0.026).
Asunto(s)
Compuestos de Azabiciclo/efectos adversos , Hipnóticos y Sedantes/efectos adversos , Piperazinas/efectos adversos , Adulto , Compuestos de Azabiciclo/administración & dosificación , Estudios Cruzados , Método Doble Ciego , Eszopiclona , Femenino , Humanos , Hipnóticos y Sedantes/administración & dosificación , Masculino , Pruebas Neuropsicológicas , Piperazinas/administración & dosificación , Desempeño Psicomotor/efectos de los fármacos , Factores de TiempoRESUMEN
PURPOSE: Based on an internal request, GlaxoSmithKline conducted a retrospective pooled analysis of randomized controlled trials to compare suicidality in adult subjects with restless legs syndrome (RLS) who were being treated with ropinirole. The objective was to proactively evaluate the incidence of potentially suicidal thoughts or behaviors (suicidality) among patients with RLS treated with ropinirole immediate release (IR) or controlled release (CR). METHODS: The US Food and Drug Administration approved methods previously used for the retrospective analysis of suicidality with antidepressants and anticonvulsants. Potential cases of suicidal thoughts and behavior were identified from searches of treatment-emergent adverse event preferred and verbatim terms; a review of serious adverse events; and searches of a priori-identified free text comment fields in the case report forms. Blinded case reports for these potential cases, in addition to all serious adverse events, were categorized by using the Columbia Classification Algorithm of Suicide Assessment. FINDINGS: The dataset for this study comprised 1799 patients who received ropinirole (either formulation) and 1258 patients who received placebo. No signal for suicidality was detected for ropinirole in the treatment of patients with RLS. IMPLICATIONS: The pooled datasets in this study were not designed to prospectively assess for suicidal ideation or behavior. Any future studies in this area should include the collection of prespecified, detailed information regarding suicidality.
Asunto(s)
Agonistas de Dopamina/efectos adversos , Indoles/efectos adversos , Síndrome de las Piernas Inquietas/tratamiento farmacológico , Suicidio/estadística & datos numéricos , Adulto , Preparaciones de Acción Retardada , Agonistas de Dopamina/administración & dosificación , Agonistas de Dopamina/uso terapéutico , Método Doble Ciego , Femenino , Humanos , Indoles/administración & dosificación , Indoles/uso terapéutico , Masculino , Persona de Mediana Edad , Ensayos Clínicos Controlados Aleatorios como Asunto , Estudios Retrospectivos , Estados UnidosRESUMEN
BACKGROUND: The anticonvulsant lamotrigine was previously shown to be effective for bipolar depression. This study assessed the efficacy and tolerability of lamotrigine and lithium compared with placebo for the prevention of mood episodes in bipolar disorder. METHOD: During an 8- to 16-week open-label phase, lamotrigine (titrated to 200 mg/day) was added to current therapy for currently or recently depressed DSM-IV-defined bipolar I outpatients (N = 966) and concomitant drugs were gradually withdrawn. Patients stabilized on open-label treatment (N = 463) were then randomly assigned to lamotrigine (50, 200, or 400 mg/day; N = 221), lithium (0.8-1.1 mEq/L; N = 121), or placebo (N = 121) monotherapy for up to 18 months. The primary outcome measure was time from randomization to intervention (addition of pharmacotherapy) for any mood episode (depressive, manic, hypomanic, or mixed). Data were gathered from September 1997 to August 2001. RESULTS: Time to intervention for any mood episode was statistically superior (p = .029) for both lamotrigine and lithium compared with placebo-median survival times were 200, 170, and 93 days, respectively. Intervention for depression was more frequent than for mania by a factor of nearly 3:1. Lamotrigine was statistically superior to placebo at prolonging the time to intervention for a depressive episode (p = .047). The proportions of patients who were intervention-free for depression at 1 year were lamotrigine 57%, lithium 46%, and placebo 45%. Lithium was statistically superior to placebo at prolonging the time to intervention for a manic or hypomanic episode (p = .026). The proportions of patients who were intervention-free for mania at 1 year were lamotrigine 77%, lithium 86%, and placebo 72%. Headache was the most frequent adverse event for all 3 treatment groups. CONCLUSION: Lamotrigine and lithium were superior to placebo for the prevention of mood episodes in bipolar I patients, with lamotrigine predominantly effective against depression and lithium predominantly effective against mania.